Scleroderma Mimics

详细信息    查看全文

• 作者：Jennifer Nashel (1)
  Virginia Steen (2)
  
• 关键词：Scleroderma mimics ; Morphea ; Localized scleroderma ; Scleredema ; Scleredema of Buschke ; Scleredema adultorum ; Scleredema diabeticorum ; Diabetic cheiroarthropathy ; Limited joint mobility syndrome ; Scleromyxedema ; Lichen myxedematosus ; Nephrogenic systemic fibrosis ; Eosinophilic fasciitis
• 刊名：Current Rheumatology Reports
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：14
• 期：1
• 页码：39-46
• 全文大小：139KB
• 参考文献：1. 鈥?Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64(2):217鈥?8. / This is an excellent review of the spectrum of morphea and localized scleroderma.
  2. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2005.
  3. 鈥?Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64(2):231鈥?2. / This is an important summary on the direction in which outcome measures and treatment of localized scleroderma are moving.
  4. 鈥?Wortsman X, Gutierrez M, Saavedra T, Honeyman J. The role of ultrasound in rheumatic skin and nail lesions: a multi-specialist approach. Clin Rheumatol 2011; 30(6):739鈥?8. / This is a discussion of the use of ultrasound in evaluation of scleroderma skin.
  5. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160(5):1075鈥?2. CrossRef
  6. 鈥?Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63(7):1998鈥?006. / This is an excellent example of how a randomized controlled trial can be carried out in this rare disease.
  7. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440鈥?. CrossRef
  8. Kreuter A, Hyun J, Skrygan M, Sommer A, Tomi NS, Breuckmann F, et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res. 2006;298(6):265鈥?2. CrossRef
  9. Kreuter A, Hyun J, Skrygan M, Sommer A, Bastian A, Altmeyer P, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. 2006;155(3):600鈥?. CrossRef
  10. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355鈥?. CrossRef
  11. Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, et al. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol. 2006;25(1):3鈥?5. CrossRef
  12. Meguerditchian C, Jacquet P, Beliard S, Benderitter T, Valero R, Carsuzza F, et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes Metab. 2006;32(5 Pt 1):481鈥?. CrossRef
  13. Ikeda Y, Suehiro T, Abe T, Yoshida T, Shinoki T, Tahara K, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Intern Med. 1998;37(10):861鈥?. CrossRef
  14. Thumpimukvatana N, Wongpraparut C, Lim HW. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol. 2010;37(12):1036鈥?. CrossRef
  15. Alsaeedi SH, Lee P. Treatment of scleredema diabeticorum with tamoxifen. J Rheumatol. 2010;37(12):2636鈥?. CrossRef
  16. Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complications. 1989;3(2):77鈥?7. CrossRef
  17. Rosenbloom AL. Diabetic thick skin and stiff joints. Diabetologia. 1989;32(1):74鈥?. CrossRef
  18. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10鈥?0. CrossRef
  19. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42(1):31鈥?. CrossRef
  20. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273鈥?1. CrossRef
  21. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37鈥?3. CrossRef
  22. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107(2):463鈥?. CrossRef
  23. Laimer M, Namberger K, Massone C, Koller J, Emberger M, Pleyer L, et al. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. Acta Derm Venereol. 2009;89(6):631鈥?. CrossRef
  24. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000鈥?. CrossRef
  25. 鈥?Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol 2010; 2(11):427鈥?3. / This is an important summary of the relationship of gadolinium to NSF.
  26. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment鈥攔eport of 33 cases. Radiology. 2009;250(2):371鈥?. CrossRef
  27. Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis鈥攁 rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61(5):868鈥?4. CrossRef
  28. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47(5):833鈥?0. vi. CrossRef
  29. Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol. 2008;144(11):1527鈥?. CrossRef
  30. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543鈥?. CrossRef
  31. Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. 2011;26(3):1099鈥?01. CrossRef
  32. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70鈥?6.
  33. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30聽years after鈥攚hat do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93鈥?01. CrossRef
  34. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47(1):29鈥?5. CrossRef
  35. Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol. 1995;22(3):563鈥?.
  36. Baumann F, Bruhlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005;184(1):169鈥?4.
  37. Barnes L, Rodnan GP, Medsger TA. Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979;96(2):493鈥?18.
  
• 作者单位：Jennifer Nashel (1)
  Virginia Steen (2)
  
  1. BIDMC, Division of Rheumatology and Lupus Center, Harvard University School of Medicine, 110 Francis Street, Suite 4B, Boston, MA, 02215, USA
  2. Georgetown University School of Medicine, 3800 Reservoir Road, PHC 3004, Washington, DC, 20007, USA
  

文摘

Scleroderma is a rare systemic autoimmune disease with multiple organ manifestations, including skin fibrosis. The groups of disorders classified as scleroderma mimics share the common thread of skin thickening but are otherwise quite incongruous in terms of underlying disease process and other organ involvement. This article reviews the clinical presentation, etiology, and treatment options available for scleroderma mimics, including morphea, scleredema, diabetic cheiroarthropathy, scleromyxedema, nephrogenic systemic fibrosis, and eosinophilic fasciitis. Through greater understanding of these diseases and the associated extradermal implications, we hope to facilitate recognition of scleroderma and its mimics.